Anti-inflammatory peptides: what calming chronic inflammation could do for you

Inflammation isn’t the enemy. The version that saves you — the heat and swelling around a fresh cut or a torn muscle — is the body doing its job well. The problem is the version that never switches off.

That low, background burn is the one worth caring about. It builds quietly, over years. It tracks with stiff joints, slower recovery, foggier thinking, and many of the diseases that shorten a life. The longevity field has a name for it: inflammaging. And a small class of peptides might be able to turn the dial down.

What calming inflammation could do for you

Here’s why that matters for you specifically. When the background burn drops, the body gets out of its own way.

Recovery is the clearest case. A tendon or a muscle stuck in a low simmer of inflammation heals slower — the signal that should say repair finished never quite arrives, so the tissue stays half-mended. Quiet that signal and the repair machinery can close the job out. The same logic runs through joints that never fully settle, a gut lining that stays irritated, skin that won’t calm down.

Then there’s the long game. If chronic inflammation really is one of the engines under ageing itself — and the evidence that it is keeps getting stronger — then a tool that turns it down is aimed at the process, not one symptom. That’s the exciting part. Not a cream for a single problem. A dial on the thing sitting underneath a lot of them.

Three peptides, three ways into the same fire

Now the genuinely interesting part — and the reason this is a class, not one molecule.

Chronic inflammation mostly runs through a single master switch inside your cells. Flip it on and the cell starts making the alarm chemicals that pull in more immune cells, which make more alarm chemicals, and the loop feeds itself. Most anti-inflammatory peptides work by quieting that switch. Three peptides now under FDA review each reach it from a different direction.

KPV is the most direct. It’s a three-amino-acid fragment — Lys-Pro-Val — snipped off the end of a natural calm-down hormone your body already makes, and the mechanism review by Brzoska and colleagues (2010) is where that case is laid out. It keeps the anti-inflammatory half of the parent hormone and drops the part that changes skin pigment. In cell and animal systems it quiets the switch and the alarm chemicals directly. The most-cited animal result is a 2008 study in mouse colitis, where it cut gut inflammation dose by dose. The full KPV story sits in our KPV explainer.

BPC-157 doesn’t fight the fire head-on. It protects the cells so they never raise the alarm in the first place — mostly by keeping blood supply and repair signalling switched on around damaged tissue. Its primary research group, Predrag Sikirić’s lab in Zagreb, has argued across three decades of rat work that the anti-inflammatory effect is a knock-on benefit of that protection rather than a direct hit on the immune signal. That animal evidence is surveyed in a 2025 review and debated in a 2025 comment exchange. We go deeper on it in our BPC-157 file.

GHK-Cu works on the neighbourhood, not the cell alone. It’s a copper-carrying peptide your body makes less of every year, and it tunes the tissue-remodelling machinery and gene programmes that either fuel or resolve inflammation — including the ageing-linked version of that same master switch, per Pickart and Margolina (2018) and Pickart and colleagues (2015). It’s the one most tied to the longevity case. The full GHK-Cu story lives in our GHK-Cu explainer.

Here’s the boundary

This is where the excitement has to earn its keep.

None of the three has a controlled human trial in an inflammatory condition. Not one. The KPV evidence is a mechanism review and that mouse colitis study. The BPC-157 evidence is thirty years of rat work plus a hamstring-injury trial that only began recruiting in 2026 — and even that one measures whether the injury heals, not whether inflammation dropped. The GHK-Cu inflammation evidence lives in cells, animals, and gene readouts; its single proper human trial was a 2006 skincare study that came back null on every objective measure.

So the mechanism is real, and it’s consistent across a lot of animal work. The human proof isn’t there yet. That’s not a reason to dismiss it — it’s the exact gap a legitimate clinical route exists to close. Hope with your eyes open.

Where the regulators sit

The regulators are looking at all three right now — on two different timelines.

KPV and BPC-157 are both on the FDA’s July 2026 compounding review, per Federal Register notice 2026-07361 — KPV under wound healing and inflammatory conditions, BPC-157 under ulcerative colitis. GHK-Cu isn’t on that July wave. It’s scheduled for the next review instead, before the end of February 2027, and specifically the injectable form that the off-label market sells. What a review like that actually decides, and what it doesn’t, is a longer story — we walk through it in what a PCAC review actually is.

One more thing if you compete in tested sport. The three don’t share a status. BPC-157 is treated as banned in and out of competition; KPV and GHK-Cu aren’t named on the current WADA list. Anti-doping status can move — check the code on the day.

The legitimate way in

There’s a proper way to get access to this, and it’s worth waiting for.

A physician prescribing against a real indication. A US-licensed pharmacy compounding it. A test on every batch before it ships. Wolverine Health is being built to be exactly that — the legitimate version of what people are already buying the grey-market way. It can’t open until the regulation catches up, and that’s the honest reason it hasn’t yet. Two dates set the clock: the July 2026 review, and the February 2027 one behind it. Tell us where to reach you, and we’ll send one note the day the science on turning down that background burn gets a real clinical home.